A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer

1Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-90. doi: 10.1200/JCO.2009.26.2543 Auperin A Le Pechoux C Rolland E Curran WJ Furuse K Fournel P Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 2010 28 218190 10.1200/JCO.2009.26.2543Open DOISearch in Google Scholar

2Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2012; 82: 425-44. doi: 10.1016/j.ijrobp.2010.09.004 Machtay M Bae K Movsas B Paulus R Gore EM Komaki R Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 2012 82 42544 10.1016/j.ijrobp.2010.09.004Open DOISearch in Google Scholar

3Schild SE, Stella PJ, Geyer SM, Bonner JA, Marks RS, McGinnis WL, et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54: 370-8. doi: 10.1016/S0360-3016(02)02930-9 Schild SE Stella PJ Geyer SM Bonner JA Marks RS McGinnis WL Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2002 54 3708 10.1016/S0360-3016(02)02930-9Open DOISearch in Google Scholar

4Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-99. doi: 10.1200/JCO.1999.17.9.2692 Furuse K Fukuoka M Kawahara M Nishikawa H Takada Y Kudoh S Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 1999 17 269299 10.1200/JCO.1999.17.9.2692Open DOISearch in Google Scholar

5Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23: 5910-7. doi: 10.1200/JCO.2005.03.070 Fournel P Robinet G Thomas P Souquet PJ Lena H Vergnenegre A Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study J Clin Oncol 2005 23 59107 10.1200/JCO.2005.03.070Open DOISearch in Google Scholar

6Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98. doi: 10.1016/j.lungcan.2004.03.004 Zatloukal P Petruzelka L Zemanova M Havel L Janku F Judas L Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study Lung Cancer 2004 46 8798 10.1016/j.lungcan.2004.03.004Open DOISearch in Google Scholar

7Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23: 5883-91. doi: 10.1200/JCO.2005.55.405 Belani CP Choy H Bonomi P Scott C Travis P Haluschak J Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol J Clin Oncol 2005 23 588391 10.1200/JCO.2005.55.405Open DOISearch in Google Scholar

8Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103: 1452-60. doi: 10.1093/jnci/djr325 Curran WJ Jr Paulus R Langer CJ Komaki R Lee JS Hauser S Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 J Natl Cancer Inst 2011 103 145260 10.1093/jnci/djr325Open DOISearch in Google Scholar

9Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol 2010; 28: 2475-80. doi: 10.1200/JCO.2009.27.1205 Bradley JD Bae K Graham MV Byhardt R Govindan R Fowler J Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117 J Clin Oncol 2010 28 247580 10.1200/JCO.2009.27.1205Open DOISearch in Google Scholar

10Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1106-11. doi: 10.1016/j.ijrobp.2006.02.046 Schild SE McGinnis WL Graham D Hillman S Fitch TR Northfelt D Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2006 65 110611 10.1016/j.ijrobp.2006.02.046Open DOISearch in Google Scholar

11Lee CB, Stinchcombe TE, Moore DT, Morris DE, Hayes DN, Halle J, et al. Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol 2009; 4: 74-9. doi: 10.1097/JTO.0b013e3181915028 Lee CB Stinchcombe TE Moore DT Morris DE Hayes DN Halle J Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer J Thorac Oncol 2009 4 749 10.1097/JTO.0b013e3181915028Open DOISearch in Google Scholar

12Blackstock AW, Ho C, Butler J, Fletcher-Steede J, Case LD, Hinson W, et al. Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol 2006; 1: 434-40. doi: 10.1016/S1556-0864(15)31608-7 Blackstock AW Ho C Butler J Fletcher-Steede J Case LD Hinson W Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer J Thorac Oncol 2006 1 43440 10.1016/S1556-0864(15)31608-7Open DOISearch in Google Scholar

13Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187-99. doi: 10.1016/S1470-2045(14)71207-0 Bradley JD Paulus R Komaki R Masters G Blumenschein G Schild S Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study Lancet Oncol 2015 16 18799 10.1016/S1470-2045(14)71207-0Open DOISearch in Google Scholar

14Belderbos J, Walraven I, van Diessen J, Verheij M, de Ruysscher D. Radiotherapy dose and fractionation for stage III NSCLC. Lancet Oncol 2015; 16: e156-7. doi: 10.1016/S1470-2045(15)70121-X Belderbos J Walraven I van Diessen J Verheij M de Ruysscher D Radiotherapy dose and fractionation for stage III NSCLC Lancet Oncol 2015 16 e1567 10.1016/S1470-2045(15)70121-XOpen DOISearch in Google Scholar

15Kerr KM, Lamb D. Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. Br J Cancer 1984; 50: 343-9. PMID: 6087867 Kerr KM Lamb D Actual growth rate and tumour cell proliferation in human pulmonary neoplasms Br J Cancer 1984 50 3439 PMID: 6087867Search in Google Scholar

16Trott KR. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys 1990; 19: 1071-5. doi: 10.1016/0360-3016(90)90036-J Trott KR Cell repopulation and overall treatment time Int J Radiat Oncol Biol Phys 1990 19 10715 10.1016/0360-3016(90)90036-JOpen DOISearch in Google Scholar

17Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005; 63: 667-71. doi: 10.1016/j.ijrobp.2005.03.037 Machtay M Hsu C Komaki R Sause WT Swann RS Langer CJ Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience Int J Radiat Oncol Biol Phys 2005 63 66771 10.1016/j.ijrobp.2005.03.037Open DOISearch in Google Scholar

18Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 2000; 46: 516-7. doi: 10.1016/S0360-3016(99)00364-8 Fowler JF Chappell R Non-small cell lung tumors repopulate rapidly during radiation therapy Int J Radiat Oncol Biol Phys 2000 46 5167 10.1016/S0360-3016(99)00364-8Open DOISearch in Google Scholar

19Brower JV, Amini A, Chen S, Hullett CR, Kimple RJ, Wojcieszynski AP, et al. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. Ann Oncol. 2016; 27: 1887-94. doi: 10.1093/annonc/mdw276 Brower JV Amini A Chen S Hullett CR Kimple RJ Wojcieszynski AP Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database Ann Oncol 2016 27 188794 10.1093/annonc/mdw276Open DOISearch in Google Scholar

20Yamoah K, Showalter TN, Ohri N. Radiation therapy intensification for solid tumors: a systematic review of randomized trials. Int J Radiat Oncol Biol Phys 2015; 93: 737-45. doi:10.1016/j.ijrobp.2015.07.2284 Yamoah K Showalter TN Ohri N Radiation therapy intensification for solid tumors: a systematic review of randomized trials Int J Radiat Oncol Biol Phys 2015 93 73745 10.1016/j.ijrobp.2015.07.2284Open DOISearch in Google Scholar

21Ramroth J, Cutter DJ, Darby SC, Higgins GS, McGale P, Partridge M, et al. Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 2016; 96: 736-47. doi: 10.1016/j.ijrobp.2016.07.022 Ramroth J Cutter DJ Darby SC Higgins GS McGale P Partridge M Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: meta-analysis of randomized trials Int J Radiat Oncol Biol Phys 2016 96 73647 10.1016/j.ijrobp.2016.07.022Open DOISearch in Google Scholar

22Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 49: 23-33. doi: 10.1016/S0360-3016(00)01374-2 Mehta M Scrimger R Mackie R Paliwal B Chappell R Fowler J A new approach to dose escalation in non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2001 49 2333 10.1016/S0360-3016(00)01374-2Open DOISearch in Google Scholar

23Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997; 350: 161-5. doi: 10.1016/S0140-6736(97)06305-8 Saunders M Dische S Barrett A Harvey A Gibson D Parmar M Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee Lancet 1997 350 1615 10.1016/S0140-6736(97)06305-8Open DOISearch in Google Scholar

24Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011; 100: 76-85. doi: 10.1016/j.radonc.2011.06.031 Baumann M Herrmann T Koch R Matthiessen W Appold S Wahlers B Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC) Radiother Oncol 2011 100 7685 10.1016/j.radonc.2011.06.031Open DOISearch in Google Scholar

25Mauguen A, Le Pechoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 2788-97. doi: 10.1200/JCO.2012.41.6677 Mauguen A Le Pechoux C Saunders MI Schild SE Turrisi AT Baumann M Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis J Clin Oncol 2012 30 278897 10.1200/JCO.2012.41.6677Open DOISearch in Google Scholar

26Din OS, Harden SV, Hudson E, Mohammed N, Pemberton LS, Lester JF, et al. Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. Radiother Oncol 2013; 109: 8-12. doi: 10.1016/j. radonc.2013.07.014 Din OS Harden SV Hudson E Mohammed N Pemberton LS Lester JF Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres Radiother Oncol 2013 109 812 10.1016/j radonc.2013.07.014Open DOISearch in Google Scholar

27Sun LM, Leung SW, Wang CJ, Chen HC, Fang FM, Huang EY, et al. Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: preliminary report of a prospective randomized study. Int J Radiat Oncol Biol Phys 2000; 47: 413-8. doi: 10.1016/S0360-3016(00)00429-6 Sun LM Leung SW Wang CJ Chen HC Fang FM Huang EY Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: preliminary report of a prospective randomized study Int J Radiat Oncol Biol Phys 2000 47 4138 10.1016/S0360-3016(00)00429-6Open DOISearch in Google Scholar

28Kaster TS, Yaremko B, Palma DA, Rodrigues GB. Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer 2015; 16: 71-9. doi: 10.1016/j.cllc.2014.08.002 Kaster TS Yaremko B Palma DA Rodrigues GB Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature Clin Lung Cancer 2015 16 719 10.1016/j.cllc.2014.08.002Open DOISearch in Google Scholar

29Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tome WA, et al. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol 2013; 31: 4343-8. doi: 10.1200/JCO.2013.51.5353 Cannon DM Mehta MP Adkison JB Khuntia D Traynor AM Tome WA Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer J Clin Oncol 2013 31 43438 10.1200/JCO.2013.51.5353Open DOISearch in Google Scholar

30Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol 2012; 7: 1382-93. doi: 10.1097/JTO.0b013e318260e00d Grills IS Hope AJ Guckenberger M Kestin LL Werner-Wasik M Yan D A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy J Thorac Oncol 2012 7 138293 10.1097/JTO.0b013e318260e00dOpen DOISearch in Google Scholar

31Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2: S94-100. doi: 10.1097/JTO.0b013e318074de34 Onishi H Shirato H Nagata Y Hiraoka M Fujino M Gomi K Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study J Thorac Oncol 2007 2 S94100 10.1097/JTO.0b013e318074de34Open DOISearch in Google Scholar

32Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2013; 85: 1325-31. doi: 10.1016/j.ijrobp.2012.11.011 Feddock J Arnold SM Shelton BJ Sinha P Conrad G Chen L Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study Int J Radiat Oncol Biol Phys 2013 85 132531 10.1016/j.ijrobp.2012.11.011Open DOISearch in Google Scholar

33Karam SD, Horne ZD, Hong RL, McRae D, Duhamel D, Nasr NM. Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer. Radiat Oncol 2013; 8: 179. doi: 10.1186/1748-717X-8-179 Karam SD Horne ZD Hong RL McRae D Duhamel D Nasr NM Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer Radiat Oncol 2013 8 179 10.1186/1748-717X-8-179Open DOISearch in Google Scholar

34Higgins KA, Pillai RN, Chen Z, Tian S, Zhang C, Patel P, et al. Concomitant chemotherapy and radiotherapy with SBRT boost for unresectable stage III non-small cell lung cancer: a phase I study. J Thorac Oncol 2017; 12: 168795. doi: 10.1016/j.jtho.2017.07.036 Higgins KA Pillai RN Chen Z Tian S Zhang C Patel P Concomitant chemotherapy and radiotherapy with SBRT boost for unresectable stage III non-small cell lung cancer: a phase I study J Thorac Oncol 2017 12 168795 10.1016/j.jtho.2017.07.036Open DOISearch in Google Scholar

35Hepel JT, Leonard KL, Safran H, Ng T, Taber A, Khurshid H, et al. Stereotactic body radiation therapy boost after concurrent chemoradiation for locally advanced non-small cell lung cancer: a phase 1 dose escalation study. Int J Radiat Oncol Biol Phys 2016; 96: 1021-7. doi: 10.1016/j. ijrobp.2016.08.032 Hepel JT Leonard KL Safran H Ng T Taber A Khurshid H Stereotactic body radiation therapy boost after concurrent chemoradiation for locally advanced non-small cell lung cancer: a phase 1 dose escalation study Int J Radiat Oncol Biol Phys 2016 96 10217 10.1016/j ijrobp.2016.08.032Open DOISearch in Google Scholar

36van Baardwijk A, Reymen B, Wanders S, Borger J, Ollers M, Dingemans AM, et al. Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. Eur J Cancer 2012; 48: 2339-46. doi: 10.1016/j.ejca.2012.04.014 van Baardwijk A Reymen B Wanders S Borger J Ollers M Dingemans AM Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer Eur J Cancer 2012 48 233946 10.1016/j.ejca.2012.04.014Open DOISearch in Google Scholar

37Abramyuk A, Tokalov S, Zophel K, Koch A, Szluha Lazanyi K, Gillham C, et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol 2009; 91: 399-404. doi: 10.1016/j.radonc.2009.01.003 Abramyuk A Tokalov S Zophel K Koch A Szluha Lazanyi K Gillham C Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol 2009 91 399404 10.1016/j.radonc.2009.01.003Open DOISearch in Google Scholar

38van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012; 104: 67-71. doi: 10.1016/j.radonc.2012.03.005 van Elmpt W De Ruysscher D van der Salm A Lakeman A van der Stoep J Emans D The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer Radiother Oncol 2012 104 6771 10.1016/j.radonc.2012.03.005Open DOISearch in Google Scholar

39Salem A, Asselin MC, Reymen B, Jackson A, Lambin P, West CML, et al. Targeting hypoxia to improve non-small cell lung cancer outcome. J Natl Cancer Inst 2018; 110: 14-30. doi: 10.1093/jnci/djx160 Salem A Asselin MC Reymen B Jackson A Lambin P West CML Targeting hypoxia to improve non-small cell lung cancer outcome J Natl Cancer Inst 2018 110 1430 10.1093/jnci/djx160Open DOISearch in Google Scholar

40Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, et al. Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by (18)F-misonidazole PET/CT in patients with non-small cell lung carcinoma (RTEP5 Study). J Nucl Med 2017; 58: 1045-53. doi: 10.2967/jnumed.116.188367 Vera P Thureau S Chaumet-Riffaud P Modzelewski R Bohn P Vermandel M Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by (18)F-misonidazole PET/CT in patients with non-small cell lung carcinoma (RTEP5 Study) J Nucl Med 2017 58 104553 10.2967/jnumed.116.188367Open DOISearch in Google Scholar

41Kong FM, Frey KA, Quint LE, Ten Haken RK, Hayman JA, Kessler M, et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 2007; 25: 3116-23. doi: 10.1200/JCO.2006.10.3747 Kong FM Frey KA Quint LE Ten Haken RK Hayman JA Kessler M A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer J Clin Oncol 2007 25 311623 10.1200/JCO.2006.10.3747Open DOISearch in Google Scholar

42Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, et al. Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial. JAMA Oncol 2017; 3: 1358-65. doi: 10.1001/jamaoncol.2017.0982 Kong FM Ten Haken RK Schipper M Frey KA Hayman J Gross M Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial JAMA Oncol 2017 3 135865 10.1001/jamaoncol.2017.0982Open DOISearch in Google Scholar

43Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol 2017; 18: 202-11. doi: 10.1016/S1470-2045(16)30648-9 Scott JG Berglund A Schell MJ Mihaylov I Fulp WJ Yue B A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study Lancet Oncol 2017 18 20211 10.1016/S1470-2045(16)30648-9Open DOISearch in Google Scholar

44Vinogradskiy Y, Tucker SL, Bluett JB, Wages CA, Liao Z, Martel MK. Prescribing radiation dose to lung cancer patients based on personalized toxicity estimates. J Thorac Oncol 2012; 7: 1676-82. doi: 10.1097/JTO.0b013e318269410a Vinogradskiy Y Tucker SL Bluett JB Wages CA Liao Z Martel MK Prescribing radiation dose to lung cancer patients based on personalized toxicity estimates J Thorac Oncol 2012 7 167682 10.1097/JTO.0b013e318269410aOpen DOISearch in Google Scholar

45Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1087-96. doi: 10.1016/j.ijrobp.2006.01.052 Chang JY Zhang X Wang X Kang Y Riley B Bilton S Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2006 65 108796 10.1016/j.ijrobp.2006.01.052Open DOISearch in Google Scholar

46Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44: 201-10. doi: 10.1016/S0360-3016(98)00544-6 Kanai T Endo M Minohara S Miyahara N Koyama-ito H Tomura H Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy Int J Radiat Oncol Biol Phys 1999 44 20110 10.1016/S0360-3016(98)00544-6Open DOISearch in Google Scholar

47Higgins KA, O’Connell K, Liu Y, Gillespie TW, McDonald MW, Pillai RN, et al. National Cancer Database analysis of proton versus photon radiation therapy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2017; 97: 128-37. doi: 0.1016/j.ijrobp.2016.10.001 Higgins KA O’Connell K Liu Y Gillespie TW McDonald MW Pillai RN National Cancer Database analysis of proton versus photon radiation therapy in non-small cell lung cancer Int J Radiat Oncol Biol Phys 2017 97 12837 0.1016/j.ijrobp.2016.10.001Open DOISearch in Google Scholar

48Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study. JAMA Oncol 2017; 3: e172032. doi: 10.1001/jamaoncol.2017.2032 Chang JY Verma V Li M Zhang W Komaki R Lu C Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study JAMA Oncol 2017 3 e172032 10.1001/jamaoncol.2017.2032Open DOISearch in Google Scholar

49Liao Z, Lee JJ, Komaki R, Gomez DR, O’Reilly MS, Fossella FV, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol 2018; 36: 1813-22. doi: 10.1200/JCO.2017.74.0720 Liao Z Lee JJ Komaki R Gomez DR O’Reilly MS Fossella FV Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer J Clin Oncol 2018 36 181322 10.1200/JCO.2017.74.0720Open DOISearch in Google Scholar

50Takahashi W, Nakajima M, Yamamoto N, Yamashita H, Nakagawa K, Miyamoto T, et al. A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC). Cancer 2015; 121: 1321-7. doi: 10.1002/cncr.29195 Takahashi W Nakajima M Yamamoto N Yamashita H Nakagawa K Miyamoto T A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC) Cancer 2015 121 13217 10.1002/cncr.29195Open DOISearch in Google Scholar

51Karube M, Yamamoto N, Shioyama Y, Saito J, Matsunobu A, Okimoto T, et al. Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters. J Radiat Res 2017; 58: 761-4. doi: 10.1093/jrr/rrx037 Karube M Yamamoto N Shioyama Y Saito J Matsunobu A Okimoto T Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters J Radiat Res 2017 58 7614 10.1093/jrr/rrx037Open DOISearch in Google Scholar

52Shirai K, Kawashima M, Saitoh JI, Abe T, Fukata K, Shigeta Y, et al. Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer - a pilot study. PLoS One. 2017; 12: e0175589. doi: 10.1371/journal.pone.0175589 Shirai K Kawashima M Saitoh JI Abe T Fukata K Shigeta Y Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer - a pilot study PLoS One 2017 12 e0175589 10.1371/journal.pone.0175589Open DOISearch in Google Scholar